4DN Stock Overview
Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States.
| Snowflake Score | |
|---|---|
| Valuation | 4/6 |
| Future Growth | 1/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Rewards
Risk Analysis
Denali Therapeutics Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$17.67 |
| 52 Week High | US$30.35 |
| 52 Week Low | US$15.47 |
| Beta | 1.33 |
| 1 Month Change | -4.23% |
| 3 Month Change | 12.34% |
| 1 Year Change | -24.15% |
| 3 Year Change | -65.43% |
| 5 Year Change | n/a |
| Change since IPO | 3.55% |
Recent News & Updates
Recent updates
Shareholder Returns
| 4DN | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | -0.2% | 0.5% |
| 1Y | -24.2% | -22.8% | 1.3% |
Return vs Industry: 4DN underperformed the German Biotechs industry which returned -23% over the past year.
Return vs Market: 4DN underperformed the German Market which returned 2.3% over the past year.
Price Volatility
| 4DN volatility | |
|---|---|
| 4DN Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 5.0% |
| Market Average Movement | 4.8% |
| 10% most volatile stocks in DE Market | 10.2% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: 4DN's share price has been volatile over the past 3 months.
Volatility Over Time: Insufficient data to determine 4DN's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2013 | 445 | Ryan Watts | www.denalitherapeutics.com |
Denali Therapeutics Inc., a biopharmaceutical company, develops a portfolio of product candidates engineered to cross the blood-brain barrier for neurodegenerative diseases and lysosomal storage diseases in the United States. The company’s transport vehicle (TV)-enabled programs include DNL310 ETV, an IDS enzyme replacement therapy program for MPS II; TAK-594/DNL593 which is in Phase 1/II for frontotemporal dementia-granulin; DNL126 program for MPS IIIA; and DNL622 for MPS I, as well as other preclinical programs that target amyloid beta and HER2. Its brain-penetrant small molecule programs comprise BIIB122/DNL151 LRRK2 inhibitor program for Parkinson's disease; SAR443820/DNL788 RIPK1 inhibitor program for CNS disease; DNL343 eIF2B Activator program for amyotrophic lateral sclerosis; and SAR443122/DNL758 RIPK1 inhibitor program for peripheral inflammatory diseases.
Denali Therapeutics Inc. Fundamentals Summary
| 4DN fundamental statistics | |
|---|---|
| Market cap | €2.07b |
| Earnings (TTM) | -€135.61m |
| Revenue (TTM) | €308.65m |
6.7x
P/S Ratio-15.3x
P/E RatioIs 4DN overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| 4DN income statement (TTM) | |
|---|---|
| Revenue | US$330.53m |
| Cost of Revenue | US$423.88m |
| Gross Profit | -US$93.34m |
| Other Expenses | US$51.88m |
| Earnings | -US$145.22m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -1.02 |
| Gross Margin | -28.24% |
| Net Profit Margin | -43.94% |
| Debt/Equity Ratio | 0% |
How did 4DN perform over the long term?
See historical performance and comparison